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Abstract 
Following protein adsorption/activation which is the first step after the contact of material surfaces 
and whole blood (part 2), fibrinogen is converted to fibrin and platelets become activated and 
assembled in the form of a thrombus. This thrombus formation is the key feature that needs to be 
minimized in the creation of materials with low thrombogenicity. Further aspects of blood 
compatibility that are important on their own are complement and leukocyte activation which are 
also important drivers of thrombus formation. Hence this chapter summarizes the state of 
knowledge on all of these cascades and cells and their interactions. For each cascade or cell type, 
the chapter distinguishes that which is in widespread agreement from what there is less of a 
consensus. 
Statement of significance 
This paper is part 3 of a series of 4 reviews discussing the problem of biomaterial associated 
thrombogenicity. The objective was to highlight features of broad agreement and provide 
commentary on those aspects of the problem that were subject to dispute. We hope that future 




Biomaterials at once activate several defense systems of the body, Figure 1. The humoral systems 





more interactions between thrombogenic and immunologic processes have been discovered. We 
discuss those systems separately and then refer to the manifold interactions at the relevant sections. 
Coagulation Cascade 
Biomaterials drive the generation of thrombin and the conversion of fibrinogen to fibrin 
necessitating the administration of heparin or other anticoagulants. The cascade of clotting 
factors beginning with Factor XII are amongst those in the protein adsorbate [1]. Activation 
of the coagulation pathway also activates the kinin-kallikrein system (via FXIIa), 
complement (via Factor XIIa, kallikrein, thrombin) and platelets (via thrombin). When 
endothelium is damaged, for example via biomaterial implantation, thrombomodulin levels 
decrease and tissue factor increases creating another source of thrombin [2] and the potential 
for activation of the intrinsic pathway via thrombin-mediated activation of FXI.  
Follow on comments: 
In the absence of biomaterials, tissue factor is regarded as the key driver of coagulation following 
vascular injury. Biomaterial associated coagulation on the other hand can be related to the surface 
activity of contact phase molecules, which have a relatively strong abundance in the protein 
adsorbate, suggesting a prominent role for contact activation. Also polyphosphate nanoparticles 
on activated blood platelets were reported to activate coagulation via Factor XII [3]. However, it 
is interesting to note that under physiological conditions, the absence of Factor XII or other contact 
proteins (HMWK, kallikrein) has not been associated with abnormal bleeding [4]. Overall, 
evidence seems to suggest that FXII activation by biomaterial contact activates the intrinsic 
coagulation cascade, leading to formation of a clot. Yet there are other pathways that may augment 
or even replace the contact activation proteins in inducing biomaterial-induced coagulation.  
The surface of activated blood platelets accelerate the coagulation cascade to produce thrombin, 
providing an amplification path that also links platelet and protein-mediated thrombosis [5]. 
There are multiple links between inflammatory and coagulant pathways. The role of blood born 
tissue factor in leukocytes and perhaps blood platelets [6, 7] in thrombosis and blood clot 
propagation has been highlighted [8, 9], and consequently some have argued that leukocyte 
activation and tissue factor release (and the extrinsic pathway) are key drivers also for biomaterial 
induced coagulation in blood [10-13]. On the other hand, the relevance of blood-born tissue factor 
for initiation of the coagulation (in distinction to propagation) is not generally accepted. A 
correlation between leukocyte inflammatory response and tissue factor expression has been 
demonstrated in vitro [11]. While the contribution of tissue factor (TF) involvement in the 
initiation of clotting in an ovine hemodialysis-model was shown [13], a correlation between 
leukocyte activation and blood clotting could not be demonstrated under defined in vitro 
conditions [11]. The rapid inactivation of tissue factor in blood has been regarded as the reason for 
this. 
The impact of neutrophil elastase and cathepsin G on clot formation has also recently been further 
demonstrated in mice and highlights the complexity of the interactions taking place in clot 
formation and growth [14, 15]. 
Factor VII activating protease (FSAP or hyaluronic acid binding protein 2: HABP2) is a serine 





pathway inhibitor and by direct FVII activation. FSAP is activated by positively charged 
macromolecules [16] and surfaces [17] and may present an additional pathway of biomaterial 
induced coagulation activation. 
Reliable analysis of blood coagulation has to reflect the complexity of the different activation 
pathways. Clotting times using whole blood or plasma using one of the established methods are 
crude measures of the ability of a material to activate the coagulation cascade. Whether plasma or 
whole blood is used to assess the properties of a test material further is a critical parameter. The 
pure initiation of the coagulation cascade does not necessarily lead to thrombus formation, but, as 
indicated above, the propagation from coagulation to the clot requires the presence of activated 
platelets [5].  
Thrombin as a parameter of blood clotting is difficult to measure directly, because it is inactivated 
within seconds to the thrombin-antithrombin (TAT) complex, especially in presence of heparin. 
Prothrombin F1+2 fragment as byproduct of thrombin formation, the TAT-complex or 
fibrinopeptide A as byproduct of fibrin activation present more useful integral parameters of 
coagulation activation. More sophisticated measures such as thrombin generation rate may be 
more useful since one can incorporate such measures in mathematical models that may enable 
predictions under a wider range of experimental and perhaps even real-world conditions. A critical 
thrombin generation rate constant was one such parameter that was defined [18]. 
Ultimately though, all materials will drive plasma to coagulate following material contact unless 
anticoagulants are used. These levels of coagulation may not be clinically significant in many 
applications, but under in vitro conditions, placing blood in contact with a synthetic material will 
ultimately result in formation of a clot [19]. The lack of clinically significant levels of coagulation 
may arise from the dilutional effects of blood flow or from the continued presence of natural 
anticoagulants.  
The need to use anticoagulants during blood collection argues against the above noted key role of 
tissue factor, although it is possible that clot initiation happens prior to the blood hitting the test 
tube. In that case though, one could not produce a blood sample that would not clot, effectively 
muting the ability to even study the problem anywhere other than in a person implanted with a 
material, and post-surgical recovery.  
Hemolysis can influence thrombosis [20-22] through an effect on coagulation and other processes, 
although this is not well studied in the context of biomaterials. It has been thought that hemolysis 
is a consequence of shear stress in a device such as in a left ventricular assist device and not an 








Platelet activation through biomaterials occurs via adhesion to adsorbed proteins (mainly 
fibrinogen) and indirectly through biomaterials-induced activation of coagulation and other 
systems. Platelet activation leads to spreading, a change in shape [23] and adhesion to 
surfaces as well as to platelets or to other cells via the GPIIb/IIIa receptor and P-selectin. It 
boosts the coagulation cascade by expression of phosphatidylserine, leads to the formation 
of microparticles, thromboxane formation and release of granule content [5, 24, 25]. These 
activated platelets create a nidus for thrombin generation and ultimately, occlusive 
thrombus formation or embolization. Such activation by biomaterials has been noted in 
experimental animals in several clinical scenarios [26-28]. In other situations, platelet 
activation is a useful diagnostic of potentially adverse interactions [27, 29].  
Follow on comments 
Material surface properties will affect the exposure of platelet binding regions in adsorbed 
proteins, and therefore affect the adhesion/activation of platelets. There are good correlations 
between the exposure of the -chain dodecapeptide in fibrinogen and platelet adhesion [30-32].  
Platelet activation can occur with but also without adhesion to a material surface [26, 27]. 
Frequently, the activation level of adherent blood platelets is used as a measure of thrombogenicity 
and scored according to the platelet morphology. Small non-spreading cells are regarded as least 
activated while a pancake-like appearance show the highest activation level with several levels of 
pseudopod formation as intermediate stages [23, 33]. However, the platelet density on a surface 
and their morphology do not always correlate with thrombogenicity: various hydrogels are not 
thrombo-adhesive, but they support platelet aggregation and embolization. Furthermore, highly 
spreading blood platelets on hydrophobic materials are found which show clinically low 
thrombogenicity. A passivating effect of these blood platelets is assumed [34-36].  
 
Activated platelets upregulate surface receptors like GPIIb/IIIa and P-selectin (CD62P), which is 
an important marker of platelet activation in vivo. The tendency of activated platelets to form 
platelet-leukocyte aggregates and stick to surfaces may suppress the level of detected P-selectin 
expression and raise the need for alternative parameters [37]. Release products of platelets, such 
as PF4 or β-TG release are established parameters [38, 39]. The platelet-leukocyte aggregates as 
such correlate with thrombotic events with cardiovascular devices and are suggested as a marker 
of platelet activation [40]. Material-induced aggregate formation has not been consistently 
characterized in vivo, making it difficult to correlate results from in vitro studies as well as testing 
the validity of the in vitro models used. 
Platelet adhesion and activation are shear dependent processes. The platelet itself is shear sensitive 
[41, 42] and von Willebrand factor (vWF), the ligand for the platelet adhesion receptor GPIb, 
undergoes shear dependent exposure of the adhesion motifs [43]. Therefore, the response of 
platelets in arterial and venous settings may be different and hemocompatibility tests need to 





on the device and thus improvement in in vitro blood compatibility due to changes in material 
chemistry may have little clinical impact, because the influence of flow predominates [44]. As an 
extreme case, modern continuous flow LVADs can lead to bleeding by destruction of the high 
molecular weight vWF multimers that are critical for platelet adhesion in capillaries [45]. 
Activated platelets release 0.1 – 1 µm sized microparticles (MPs) budding off from the cell 
membrane. Several animal and clinical studies have demonstrated that these MPs contribute to a 
pro-thrombotic state through the expression of phosphatidylserine and TF. This is true not just for 
platelets MPs but also for endothelial cells, monocytes and neutrophils MPs [46]. Cardiovascular 
materials have demonstrated to induce MP formation with significant impact on thrombosis and 
inflammation in animal experiments as well as clinical studies, highlighting the need of the 
biomaterial community to assess these as a form of material-induced activation and a 
biocompatibility marker. The presence of microparticles generated by LVAD in patients is also 
believed to contribute to endothelial dysfunction inducing a prothrombotic and pro-inflammatory 
state in patients, which can also alter the ability of endothelial cells to release vasodilatory 
mediators [47, 48]. The direct link between MPs and adverse events (such as stroke, organ failure, 
myocardial infarction), however, remains difficult to identify due to the limited number of clinical 
studies and the small number of patients involved.  
Sefton believes that complement activation (particularly at the level of C1) is important for both 
adhesion and activation of blood platelets [49]. Recent research shows that C1q binds to platelets 
and is activated, leading to further complement activation through an increase in C3a [50-52]. The 
binding of C1q occurs either through a specific C1q receptor or through P-selectin after platelet 
activation. Complement activation may occur earlier than platelet activation, although it is likely 
that there is substantive crosstalk precluding such delineation. Given the crosstalk among these 
systems, platelet and leukocyte activation also occur in an interdependent fashion, albeit to 
different extents at different times.  
In vitro platelet analysis in the frame of hemocompatibility assessment has several limitations. It 
is difficult to determine when platelet activation by a biomaterial, observed in in vitro assays, 
becomes clinically relevant; the same is generally true for any hemocompatibility parameter. 
Consequently, use of the term “highly activating” is of limited value without quantitative 
definition. Despite evidence that platelet functions and reactivity from patients with cardiovascular 
disease differ from healthy individuals [53-55], pre-clinical in vitro studies continue to be 
performed with the blood of healthy donors. This estimation of hemocompatibility therefore does 








The complement system, made up from more than 30 proteins is evolutionary related to the 
blood coagulation cascade and contributes to host defense. Biomaterials activation of the 
complement cascade leads to the release of reactive fragments C3a, C5a and SC5b-9 to 
plasma while complement proteins including C1q and C3b are often found in the protein 
adsorbate [56, 57]. The alternative pathway is particularly relevant for surfaces bearing a 
nucleophile group (OH, NH2) capable of covalent binding of C3b [58, 59]. Complement 
inhibitors such as Factor H or C1q inhibitor may also bind to biomaterial surfaces or be 
incorporated into the protein adsorbate, such that complement activation is downregulated 
[60]. 
 
Follow on comments: 
Different pathways may be involved in biomaterials induced complement activation [61]. Surface 
induced activation of the alternative pathway was reported to be a consequence of nucleophilic 
surface groups – but several reports propose that this effect is conferred via adsorbed proteins and 
not via the chemical moiety itself [62, 63]. Some suggest [59] that mostly hydroxylic groups are 
responsible for strong complement activation and activation through amino groups seems to be 
less relevant. The classical pathway may be activated by C1q binding to non-specifically adsorbed 
immunoglobins (IgG, IgM) on a foreign surface as well as to non-self patterns on surfaces and 
gets activated to initiate the complement cascade [64]. Only few reports propose a mannose 
pathway involvement through adsorbed, glycosylated proteins [65] or nanoparticles [66].  
Besides the activation of the complement cascade, biomaterials may affect also the course of the 
cascade. Complement inhibitors (Factor H, C1q inhibitor) interacting with surfaces crucially 
modulate the resulting complement activation [57]. Surface topography on a nanoscale range, like 
the high surface curvature of nanoparticles can sterically prevent the interaction of adsorbed 
complement factors and thus block the propagation of the complement cascade [67]. 
Activation of the complement system mainly has inflammatory consequences. Complement 
fragment C5a is a strong activator of myeloid leukocytes via their complement receptor C5aR1 
(CD88). The adhesion of these cells to a complement-activating surface is mainly triggered by the 
presence of surface-bound complement fragment C3b [58].  
Complement activation induced by the biomaterial at the site of implantation may also lead to 
deposition of complement products on endothelial cells and production of endothelial 
microparticles which can contribute to the pro-inflammatory and thrombotic state [68]. C1q has 
also been shown to modulate endothelial cells behavior and to play a role in angiogenesis [69]. 
While these processes have been studied in vitro and in thrombotic diseases, they have been poorly 
characterized with cardiovascular devices [68].  
The complement system also has several links to the coagulation system, both of which proceed 
in parallel in the protein adsorbate: coagulation factor XIIa can activate complement component 
C1 and thrombin can function as a C5 convertase [70]. In addition, the fibrinolytic plasmin has 
activity as a C5 convertase [71]. The complement system can modify coagulation by activating 





activator inhibitor (PAI-1) [74]. As mentioned above, activated platelets can support complement 
activation by binding complement fragments to P-selectin and the C1q receptor [49, 75]. 
Heparin acts as inhibitor in both systems by association with either antithrombin (coagulation) or 
factor H (complement).  
Complement activation in vitro is typically measured in serum, since calcium and magnesium are 
required cofactors (precluding the use of citrate or EDTA) and heparin is an inhibitor of some 
reactions but not all, complicating result interpretation. If whole blood or blood plasma has to be 
used, then hirudin can be used as anticoagulant, as it does not interact with the complement system 
[76]. The soluble fragment complement C5a is a possible analyte for the common, terminal 
complement pathway. Fast binding of C5a to its receptor on granulocytes may quench the 
concentration of the free peptide [77] and quantification of the soluble terminal complement 
complex (sC5b-9) has been suggested as a more reliable parameter to determine the activation of 
the complement cascade [78]. If differentiation between the classical or alternative pathway is 
desired, then quantification of Bb (alternative pathway) and C4d (classical pathway) or the use of 
specific inhibitors can help, however in advanced stages usually the whole complement cascade is 
activated. 
The critical threshold for complement related incompatibility is undefined, yet it is presumed that 
higher amounts indicate greater incompatibility. While 5 mg/mL SC5b-9 is readily detectable, it 








Like platelets, myeloid leukocytes (neutrophils and monocytes) may adhere or be activated 
on a surface. Their adhesion to biomaterials is mediated via different factors with adsorbed 
proteins (fibrinogen, fibronectin and iC3b) being of primary importance. Upregulation of 
CD11b, loss of L-selectin, release of reactive oxygen species (oxidative burst), neutrophil 
elastase, cathepsin G or IL-8 are typical markers of activation [79, 80]. These release 
products lead to local tissue damage and recruitment and activation of more inflammatory 
cells.  
Follow-on comments 
Triggers for leukocyte activation on materials mainly are adsorbed proteins and adherent platelets. 
Additionally, mechanical factors and contamination with endotoxins may induce leukocyte 
activation.  
Adsorbed and soluble complement products are the most prominent triggers of granulocyte and 
monocyte activation. Above all the anaphylatoxic peptides C3a and C5a induce cell activation [12] 
while adherence to the surface is mediated through surface-bound iC3b that binds to CD11b/CD18 
[81]. Other pathways, such as kallikrein-induced activation, also contribute to the activation [82] 
and adherence can occur to already adsorbed and activated platelets [83, 84]. Little is known about 
how eosinophils react to bare materials, yet there is evidence that they may become activated with 
drug-coated materials (such as stents) [85, 86]. 
Physical factors of biomedical devices, such as disturbed flow in LVAD and cardiopulmonary 
bypass (CPB), also present a source of leukocyte activation and contribute to a pro-thrombotic and 
pro-inflammatory state of leukocytes [80].   
An additional “external” factor that may also affect leukocyte activation are lipopolysaccharides 
(LPS) from Gram negative bacteria, which are also commonly known as endotoxin. They can 
easily contaminate the surface of cardiovascular devices and biomaterials synthesized in the lab 
[87]. A contaminated surface can activate several components of the inflammatory and thrombotic 
response in blood. Therefore all materials should be tested for endotoxin contamination prior to in 
vitro and in vivo studies [88, 89].  
The first innate inflammatory response against foreign materials in blood includes neutrophils and 
monocytes. When activated, internal cell reorganization will lead to the presentation of CD11b 
and other adhesion ligands on the cell surface. This enables the cells to adhere to the surface and 
to interact with other neutrophils, monocytes and platelets. Additionally, they release soluble 
factors (elastase, myeloperoxidase) and microparticle and can form neutrophil extracellular traps 
(NETs). 
Similarly to platelet microparticles, leukocyte microparticles play a role in hemostasis and 
inflammation and contribute to pathological conditions [90]. No in vitro study has yet 
characterized the mechanisms associated with material-induced leukocyte microparticles. There is 
however clinical evidence that leukocyte microparticles generated with cardiovascular devices 





Granulocyte activation also can lead to NETosis (neutrophil extracellular trap formation), which 
is characterized by the expulsion of nuclear DNA along with citrullinated histones and granular 
content (e.g. elastase) [91]. These components are highly thrombogenic [92] and have been 
identified in thrombi from coronary arteries [93] and from failed stents [86]. While these have 
become an area of active research in thrombosis and inflammation [94, 95], the biomaterials 
community has been slow to recognize the potential impact of NETs in biocompatibility and 
limited in vitro studies exist. Recently, Sperling and Maitz suggested that NETs may also 
contribute to biomaterial-induced thrombogenicity [96]. The formation of NETs was also observed 
on CoCr (a common biomaterial used in stents) in the presence of platelets in vitro [97]. 
It is generally considered that biomaterials do not induce an adaptive, lymphocyte dependent 
immune response [98] but this may deserve more attention in hemocompatibility research [99]. 
There are a few cases, like nickel or chromium allergy, where released ions transform self-proteins 
to foreign epitopes and induce a T-cell response. It is startling that in the absence of an antigen, T 
cells can be activated, but it was reported that cytokines at the inflammatory site around the implant 
may cause a non-clonal bystander activation of T-cells [100]. A recent paper [101] points to a 
pivotal role for B cells in the foreign body response. 
The activation of immune responses sometimes also has distinct beneficial effects. Microbial 
infection is a persistent risk for implant materials in the body and antimicrobial defense is a leading 
task of neutrophil granulocytes. The antimicrobial capacity of biomaterials-adherent neutrophils 
however is still largely unexplored [102], which significantly affects our ability to design 
cardiovascular biomaterials that can resist infection. Whole blood incubation was shown  to 
support anti-microbial activity against various gram-positive and gram-negative strains [103]. On 
the other hand, other studies indicate that neutrophils have been shown to promote bacterial growth 
and to create a protective environment for biofilms [104, 105]. 
More positive effects of material-induced inflammation were noted for endothelial regeneration 
following vascular prosthetic implants [106]. Activated neutrophils can support monocyte 
infiltration and subsequent phenotype switching may suggest a beneficial impact [107]. Since 
biomaterial implantation, inter alia, damages blood vessels, transmigration through activated 
endothelium may not be the primary mechanism for generating of monocyte-derived tissue 
macrophages. In addition, there are tissue resident macrophages that are different from the 
monocyte-derived phenotype [108]. Conversely, the inflammatory response in the surrounding 
tissue induced by cardiovascular implantation may also result in the release of macrophage wound 
healing factors that could promote endothelialization.  
In the context of an inflammatory response, the variety of cytokines generated will dictate the 
consequences of that response. Pro-inflammatory properties (M1) of macrophages activated by 
Interferon γ and pro-regenerative properties (M2) after activation by IL4 or IL10, for example, are 
observed [109] in vitro. The relevance of these clear M1/M2 distinctions in vivo is less clear, , 
although the notion of phenotypic differences among macrophages has been exploited in recent in 
vivo biomaterial studies [110, 111]. It has also been suggested that neutrophils can exhibit distinct 
phenotypes and may thus play different roles in inflammation, all the more so in the presence of 





Leukocyte activation manifests itself in diverse forms, and the mechanisms of crosstalk between 
platelets and leukocytes have been well demonstrated, blurring the line between inflammation and 
thrombosis [84]. Activated leukocytes can directly contribute to plasma coagulation on various 
pathways. They express tissue factor and contribute to coagulation in the process of thrombosis 
[12, 115-117]. The relevance of this pathway in biomaterial-associated thrombogenicity, however 
is unclear [11]. 
In addition to local effects of cell adhesion / activation systemic clinical consequences that have 
been directly related to leukocyte activation include infection, myocardial infarction as well as 
organ injury and failure [80, 118]. Leukocyte removal filters have been introduced in 
cardiopulmonary bypass (CPB) [119] yet released inflammatory mediators from the trapped cells 
could contribute to the inflammatory response [120]. 
In an in vitro model, the determination of leukocyte activation is limited to local effects. 
Additionally, usually blood donation is done by healthy donors while clinical complications may 
result from the altered state of leukocytes in ill patients. Leukocytes are generally in a state of 
higher activation in cardiovascular diseases, such as in heart failure and left ventricular dysfunction 
[121, 122]. This can further contribute to complications following implantation of a medical 
device. Preclinical hemocompatibility testing will need to address these clinical conditions better 
in the future. 
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